Over the past decade, the concept of targeting cytokines to treat autoimmune diseases has evolved at a rapid pace, such as some medicines approved by the drug administration to target IL-1β, IL-5, IL-6, IL-2, TNF-α, and IFN-γ [38]. This evidence concerns the gene IL5 and autoimmune disease.